Cancer management and research · 2026
Impact of Systematic Biopsy Core Number on Clinically Significant Prostate Cancer Detection and Complications in MRI-Ultrasound Fusion Biopsy: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Chung Yi, Chang Ying-Hsu, Lin Yu-Hsiang, Chen Po Han, Chang Chun Bi, Wang Li-Jen, Wu Chun-Te, Pang See Tong, Lee Wei Chang, Fan Le Wei, Li Yun Ren, Shao I-Hung
Аннотация
BACKGROUND: This study evaluated the impact of varying systematic biopsy (SB) core numbers on the detection rates of prostate cancer (PCa) and clinically significant PCa (csPCa) in men with magnetic resonance imaging (MRI)-suspicious lesions undergoing MRI-ultrasound fusion biopsy; and to assess biopsy-related complications.
METHODS: This retrospective, non-randomized cohort study included 356 patients who underwent multi-parametric MRI followed by MRI-ultrasound fusion targeted biopsy (TB) combined with SB for suspected PCa (Prostate Imaging Reporting and Data System score ≥ 3). Patients were divided into two groups based on the number of SB cores received: ≤ 6 SB cores (n = 200) and > 6 SB cores (n = 156). Primary outcomes were overall PCa and csPCa (Gleason Grade Group ≥ 2) detection rates. Secondary outcomes included the added diagnostic value of SB for csPCa, SB upgrading rates, and post-biopsy complications.
RESULTS: No significant difference was observed in the overall PCa detection rate between the ≤ 6 cores and > 6 cores groups (58.0% vs 50.0%, P = 0.081) or in the overall csPCa detection rate (42.5% vs 37.2%, P = 0.182). The added diagnostic value of SB for csPCa detection (3.0% vs 3.8%, P = 0.439) and SB upgrading rate (7.0% vs 9.6%, P = 0.241) were comparable between the groups. However, the complication rate was significantly lower in the group receiving ≤ 6 SB cores compared to that receiving the > 6 SB cores (15.5% vs 26.3%, P = 0.009). Subgroup analysis indicated that SB provided significantly higher added value for csPCa detection in older patients (≥ 67 years; 5.3% vs 1.6%, P = 0.049). Multivariable logistic regression demonstrated that receiving >6 SB cores was not significantly associated with increased detection of csPCa.
CONCLUSION: These findings seem support optimizing and potentially reducing the systematic component of combined biopsy. Further prospective studies are warranted to confirm these results and refine personalized biopsy protocols.
METHODS: This retrospective, non-randomized cohort study included 356 patients who underwent multi-parametric MRI followed by MRI-ultrasound fusion targeted biopsy (TB) combined with SB for suspected PCa (Prostate Imaging Reporting and Data System score ≥ 3). Patients were divided into two groups based on the number of SB cores received: ≤ 6 SB cores (n = 200) and > 6 SB cores (n = 156). Primary outcomes were overall PCa and csPCa (Gleason Grade Group ≥ 2) detection rates. Secondary outcomes included the added diagnostic value of SB for csPCa, SB upgrading rates, and post-biopsy complications.
RESULTS: No significant difference was observed in the overall PCa detection rate between the ≤ 6 cores and > 6 cores groups (58.0% vs 50.0%, P = 0.081) or in the overall csPCa detection rate (42.5% vs 37.2%, P = 0.182). The added diagnostic value of SB for csPCa detection (3.0% vs 3.8%, P = 0.439) and SB upgrading rate (7.0% vs 9.6%, P = 0.241) were comparable between the groups. However, the complication rate was significantly lower in the group receiving ≤ 6 SB cores compared to that receiving the > 6 SB cores (15.5% vs 26.3%, P = 0.009). Subgroup analysis indicated that SB provided significantly higher added value for csPCa detection in older patients (≥ 67 years; 5.3% vs 1.6%, P = 0.049). Multivariable logistic regression demonstrated that receiving >6 SB cores was not significantly associated with increased detection of csPCa.
CONCLUSION: These findings seem support optimizing and potentially reducing the systematic component of combined biopsy. Further prospective studies are warranted to confirm these results and refine personalized biopsy protocols.